Israeli DreaMed Diabetes Raises $3 Million and Partners with Abbott for Data Integration

Israeli startup DreaMed Diabetes, the developer of the AI-driven endo.digital platform for diabetes treatment, has raised $3 million in a recent funding round. Despite the CEO and co-founder Eran Atlas being called up for six months of military reserve duty with the IDF in October, the company successfully completed the round, demonstrating resilience amid challenging circumstances.

The funding round was led by eHealth Ventures, a venture capital firm specializing in early-stage digital health investments. This latest investment adds to DreaMed’s previous financial achievements, including approximately $20 million in grants and non-diluted funding, and $9.4 million raised through equity financing.

In addition to securing funding, DreaMed has also advanced its commercialization efforts, recently signing a significant data integration agreement with Abbott, a leading player in the diabetes medical device sector. This partnership allows patients to connect their FreeStyle Libre continuous glucose monitoring (CGM) data to DreaMed’s endo.digital platform via the cloud, facilitating remote monitoring and providing personalized insulin treatment recommendations to healthcare providers. The platform, which has now secured its fifth FDA approval, continues to gain traction in the healthcare industry.

Source: CTech